Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 1/2 Recruiting 50 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

This was a phase 1b/2,open label, multi-center study to assess efficacy and safety of HS-10542 in adulte patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysis.

Timeline

Start: 2026-02-14
Primary completion: 2027-05-30
Completion: 2029-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HS-10542	Small molecule	—	Oral

Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Summary

Timeline

Drugs

Indications